Cite
HARVARD Citation
Owonikoko, T. et al. (n.d.). 71PPhase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Annals of oncology. p. . [Online].